Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial.

Glüer CC, Marin F, Ringe JD, Hawkins F, Möricke R, Papaioannu N, Farahmand P, Minisola S, Martínez G, Nolla JM, Niedhart C, Guañabens N and 10 more

Show all authors

Nuti R, Martín-Mola E, Thomasius F, Kapetanos G, Peña J, Graeff C, Petto H, Sanz B, Reisinger A, Zysset PK

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 Jun 2013Cited by 108 (Europe PMC)

PMID23322362PMCIDPMC3708101DOI10.1002/jbmr.1870PepBankPUB-23322362

Download PDF PubMedAsk about this study

Jump to 7 results

Summary

Data on treatment of glucocorticoid-induced osteoporosis (GIO) in men are scarce. We performed a randomized, open-label trial in men who have taken glucocorticoids (GC) for ≥3 months, and had an areal bone mineral density (aBMD) T-score ≤ -1.5 standard deviations. Subjects received 20 μg/d teriparatide (n = 45) or 35 mg/week risedronate (n = 47) for 18 months. Primary objective was to compare lumbar spine (L1 -L3 ) BMD measured by quantitative computed tomography (QCT). Secondary outcomes included BMD and microstructure measured by high-resolution QCT (HRQCT) at the 12th thoracic vertebra, biomechanical effects for axial compression, anterior bending, and axial torsion evaluated by finite element (FE) analysis from HRQCT data, aBMD by dual X-ray absorptiometry, biochemical markers, and safety. Computed tomography scans were performed at 0, 6, and 18 months. A mixed model repeated measures analysis was performed to compare changes from baseline between groups. Mean age was 56.3 years. Median GC dose and duration were 8.8 mg/d and 6.4 years, respectively; 39.1% of subjects had a prevalent fracture, and 32.6% received prior bisphosphonate treatment. At 18 months, trabecular BMD had significantly increased for both treatments, with significantly greater increases with teriparatide (16.3% versus 3.8%; p = 0.004). HRQCT trabecular and cortical variables significantly increased for both treatments with significantly larger improvements for teriparatide for integral and trabecular BMD and bone surface to volume ratio (BS/BV) as a microstructural measure. Vertebral strength increases at 18 months were significant in both groups (teriparatide: 26.0% to 34.0%; risedronate: 4.2% to 6.7%), with significantly higher increases in the teriparatide group for all loading modes (0.005 < p < 0.015). Adverse events were similar between groups. None of the patients on teriparatide but five (10.6%) on risedronate developed new clinical fractures (p = 0.056). In conclusion, in this 18-month trial in men with GIO, teriparatide showed larger improvements in spinal BMD, microstructure, and FE-derived strength than risedronate.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In men with glucocorticoid-induced osteoporosis, teriparatide increased HRQCT integral BMD more than risedronate.
In plain wordsIn men with glucocorticoid-induced osteoporosis, teriparatide increased integral bone density more than risedronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseIntegral BMD
Study
n = 92
Comparator
Risedronate
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · 18 monthsAs given in this study (human).
Source sentences
Summary
HRQCT trabecular and cortical variables significantly increased for both treatments with significantly larger improvements for teriparatide for integral and trabecular BMD and bone surface to volume ratio (BS/BV) as a microstructural measure.
2 context sentences(design, population, supporting numbers)
Summary · context
We performed a randomized, open-label trial in men who have taken glucocorticoids (GC) for ≥3 months, and had an areal bone mineral density (aBMD) T-score ≤ -1.5 standard deviations.
Summary · context
Subjects received 20 μg/d teriparatide (n = 45) or 35 mg/week risedronate (n = 47) for 18 months.
Show in the study text Report a problemFND-2332236202
02HumanRandomized controlled trialEfficacy outcome
In men with glucocorticoid-induced osteoporosis, teriparatide increased HRQCT trabecular BMD more than risedronate.
In plain wordsIn men with glucocorticoid-induced osteoporosis, teriparatide increased trabecular bone density more than risedronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseHRQCT trabecular BMD
Study
n = 92
Comparator
Risedronate
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · 18 monthsAs given in this study (human).
Source sentences
Summary
HRQCT trabecular and cortical variables significantly increased for both treatments with significantly larger improvements for teriparatide for integral and trabecular BMD and bone surface to volume ratio (BS/BV) as a microstructural measure.
2 context sentences(design, population, supporting numbers)
Summary · context
We performed a randomized, open-label trial in men who have taken glucocorticoids (GC) for ≥3 months, and had an areal bone mineral density (aBMD) T-score ≤ -1.5 standard deviations.
Summary · context
Subjects received 20 μg/d teriparatide (n = 45) or 35 mg/week risedronate (n = 47) for 18 months.
Show in the study text Report a problemFND-2332236203
03HumanRandomized controlled trialEfficacy outcome
In men with glucocorticoid-induced osteoporosis, teriparatide improved bone surface to volume ratio more than risedronate.
In plain wordsIn men with glucocorticoid-induced osteoporosis, teriparatide improved bone surface to volume ratio more than risedronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedBone surface to volume ratio
Study
n = 92
Comparator
Risedronate
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · 18 monthsAs given in this study (human).
Source sentences
Summary
HRQCT trabecular and cortical variables significantly increased for both treatments with significantly larger improvements for teriparatide for integral and trabecular BMD and bone surface to volume ratio (BS/BV) as a microstructural measure.
2 context sentences(design, population, supporting numbers)
Summary · context
We performed a randomized, open-label trial in men who have taken glucocorticoids (GC) for ≥3 months, and had an areal bone mineral density (aBMD) T-score ≤ -1.5 standard deviations.
Summary · context
Subjects received 20 μg/d teriparatide (n = 45) or 35 mg/week risedronate (n = 47) for 18 months.
Show in the study text Report a problemFND-2332236204
04HumanRandomized controlled trialEfficacy outcome
In men with glucocorticoid-induced osteoporosis, teriparatide increased vertebral strength more than risedronate across all loading modes.
In plain wordsIn men with glucocorticoid-induced osteoporosis, teriparatide increased vertebral strength more than risedronate across all tested loading modes.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseVertebral strength across loading modes
Study
n = 92
Comparator
Risedronate
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · 18 monthsAs given in this study (human).
Measurements
Vertebral strength increase
26 to 34%
teriparatide
Vertebral strength increase
4.2 to 6.7%
risedronate
Source sentences
Summary
Vertebral strength increases at 18 months were significant in both groups (teriparatide: 26.0% to 34.0%; risedronate: 4.2% to 6.7%), with significantly higher increases in the teriparatide group for all loading modes (0.005 < p < 0.015).
2 context sentences(design, population, supporting numbers)
Summary · context
We performed a randomized, open-label trial in men who have taken glucocorticoids (GC) for ≥3 months, and had an areal bone mineral density (aBMD) T-score ≤ -1.5 standard deviations.
Summary · context
Subjects received 20 μg/d teriparatide (n = 45) or 35 mg/week risedronate (n = 47) for 18 months.
Show in the study text Report a problemFND-2332236205
05HumanRandomized controlled trialSafety outcome
In men with glucocorticoid-induced osteoporosis, adverse events were similar with teriparatide and risedronate.
In plain wordsIn men with glucocorticoid-induced osteoporosis, adverse events were similar with teriparatide and risedronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeAdverse events
Study
n = 92
Comparator
Risedronate
Analysis
Secondary
Outcome group
Adverse events · Whole body
Studied dose
20 μg/day · 18 monthsAs given in this study (human).
Source sentences
Summary
Adverse events were similar between groups.
2 context sentences(design, population, supporting numbers)
Summary · context
We performed a randomized, open-label trial in men who have taken glucocorticoids (GC) for ≥3 months, and had an areal bone mineral density (aBMD) T-score ≤ -1.5 standard deviations.
Summary · context
Subjects received 20 μg/d teriparatide (n = 45) or 35 mg/week risedronate (n = 47) for 18 months.
Show in the study text Report a problemFND-2332236206
06HumanRandomized controlled trialEfficacy outcome
In men with glucocorticoid-induced osteoporosis, teriparatide increased trabecular BMD more than risedronate.
In plain wordsIn men with glucocorticoid-induced osteoporosis, teriparatide increased trabecular bone density more than risedronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTrabecular BMD at 18 months
Study
n = 92
Comparator
Risedronate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · 18 monthsAs given in this study (human).
Measurements
BMD increase
16.3%
teriparatide
BMD increase
3.8%
risedronate
Source sentences
Summary
At 18 months, trabecular BMD had significantly increased for both treatments, with significantly greater increases with teriparatide (16.3% versus 3.8%; p = 0.004).
2 context sentences(design, population, supporting numbers)
Summary · context
We performed a randomized, open-label trial in men who have taken glucocorticoids (GC) for ≥3 months, and had an areal bone mineral density (aBMD) T-score ≤ -1.5 standard deviations.
Summary · context
Subjects received 20 μg/d teriparatide (n = 45) or 35 mg/week risedronate (n = 47) for 18 months.
Show in the study text Report a problemFND-2332236201
07HumanRandomized controlled trialEfficacy outcome
In men with glucocorticoid-induced osteoporosis, no new clinical fractures occurred with teriparatide, versus five (10.6%) with risedronate (p = 0.056).
In plain wordsIn men with glucocorticoid-induced osteoporosis, no teriparatide patients had new clinical fractures, versus five with risedronate (p = 0.056).
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeNew clinical fractures
Study
n = 92
Comparator
Risedronate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · 18 monthsAs given in this study (human).
Measurements
New clinical fractures
5 patients
risedronate
New clinical fractures
10.6%
risedronate
Source sentences
Summary
None of the patients on teriparatide but five (10.6%) on risedronate developed new clinical fractures (p = 0.056).
2 context sentences(design, population, supporting numbers)
Summary · context
We performed a randomized, open-label trial in men who have taken glucocorticoids (GC) for ≥3 months, and had an areal bone mineral density (aBMD) T-score ≤ -1.5 standard deviations.
Summary · context
Subjects received 20 μg/d teriparatide (n = 45) or 35 mg/week risedronate (n = 47) for 18 months.
Show in the study text Report a problemFND-2332236207

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00503399

Comparison of the Effects of 2 Drugs on Lumbar Spine Volumetric BMD in Men With Glucocorticoid-Induced Osteoporosis

Eli Lilly and Companyn = 92Jul 2007 to Oct 2010

Osteoporosis

Trial page ClinicalTrials.govUpdated 13 Mar 2012

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.